Want to see GRCE full AI Analyst Report?
Grace Therapeutics (GRCE) Stock Statistics & Valuation Metrics
Total Valuation
Grace Therapeutics has a market cap or net worth of $38.92M. The enterprise value is $25.45M.
- Market Cap
- $38.92M
- Enterprise Value
- $25.45M
Share Statistics
Grace Therapeutics has 21,035,930 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 21,035,930
- Owned by Insiders
- 21.34%
- Owned by Institutions
- 4.06%
Financial Efficiency
Grace Therapeutics’s return on equity (ROE) is -0.12 and return on invested capital (ROIC) is -14.10%.
- Return on Equity (ROE)
- -0.12
- Return on Assets (ROA)
- -0.12
- Return on Invested Capital (ROIC)
- -14.10%
- Return on Capital Employed (ROCE)
- -0.17
- Revenue Per Employee
- 0
- Profits Per Employee
- -1.56M
- Employee Count
- 5
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Grace Therapeutics is -1.47. Grace Therapeutics’s PEG ratio is 0.01.
- PE Ratio
- -1.47
- PS Ratio
- 0.00
- PB Ratio
- 0.66
- Price to FCF
- -2.92
- Price to Operating Cash Flow
- -3.10
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, Grace Therapeutics had revenue of 0 and earned -7.79M in profits. Earnings per share was -0.47.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -11.08M
- Pretax Income
- -9.49M
- Net Income
- -7.79M
- EBITDA
- -11.07M
- Earnings Per Share (EPS)
- -0.47
Cash Flow
In the last 12 months, operating cash flow was -10.30M and capital expenditures 0, giving a free cash flow of -10.30M billion.
- Operating Cash Flow
- -10.30M
- Free Cash Flow
- -10.30M
- Free Cash Flow per Share
- -0.60
Dividends & Yields
Grace Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -34.21%
- Earnings Yield
- -67.15%
Stock Price Statistics
- Beta
- 1.12
- 52-Week Price Change
- -39.14%
- 50-Day Moving Average
- 2.04
- 200-Day Moving Average
- 2.76
- Relative Strength Index (RSI)
- 43.65
- Average Volume (3m)
- 130.09K
Important Dates
Grace Therapeutics upcoming earnings date is Nov 16, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- Nov 16, 2026
- Ex-Dividend Date
- ―
Financial Position
Grace Therapeutics as a current ratio of 8.10, with Debt / Equity ratio of 0.00%
- Current Ratio
- 8.10
- Quick Ratio
- 8.10
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.53
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Grace Therapeutics has paid -1.70M in taxes.
- Income Tax
- -1.70M
- Effective Tax Rate
- 0.18
Enterprise Valuation
Grace Therapeutics EV to EBITDA ratio is -0.64, with an EV/FCF ratio of -1.59.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.64
- EV to Free Cash Flow
- -1.59
- EV to Operating Cash Flow
- -1.59
Balance Sheet
Grace Therapeutics has $13.76M in cash and marketable securities with $0.00 in debt, giving a net cash position of $13.76M billion.
- Cash & Marketable Securities
- $13.76M
- Total Debt
- $0.00
- Net Cash
- $13.76M
- Net Cash Per Share
- $0.65
- Tangible Book Value Per Share
- $0.72
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Grace Therapeutics is $4.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $4.00
- Price Target Upside
- 116.22% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 1
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- -43.60%
Scores
- Smart Score
- 7
- AI Score
- 49
